Actinium Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATNM research report →
Range $4 – $24.26
Price Chart
About the company
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT.
- CEO
- Sandesh C. Seth
- IPO
- 2012
- Employees
- 25
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on ATNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.01M
- P/E
- 3.24
- Fwd P/E
- 4.44
- PEG
- 0.02
- P/S
- 0.96
- P/B
- 1.37
- EV/EBITDA
- 0.55
- Div Yield
- 0.00%
- Gross Margin
- 100.51%
- Op Margin
- 26.07%
- Net Margin
- 30.27%
- ROE
- 65.18%
- ROIC
- 35.45%
Latest fiscal year · YoY change
- Revenue
- $90.00K+0.0%
- Gross Profit
- $90.00K+111.1%
- Op Income
- $-36,247,000
- Net Income
- $-33,887,000+11.4%
- EPS
- $-1.09+14.2%
- OCF Growth
- +25.7%
- FCF Growth
- +25.4%
- 52W High
- $1.72
- 52W Low
- $0.73
- 50D MA
- $1.29
- 200D MA
- $1.13
- Beta
- 0.02
- RSI (14)
- 36
- Avg Volume
- 191.69K
No earnings-call transcripts are available for ATNM yet.
- Free Float
- 99.4%
- Shares Outstanding
- 31.44M
- Float Shares
- 31.26M
of shares held by institutions
48 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.42M | ▲ 36.49K |
| Vanguard Capital Management LLC | 1.23M | ▼ 4.38K |
| Millennium Management LLC | 483.67K | ▼ 30.91K |
| Acadian Asset Management LLC | 481.00K | ▼ 15.29K |
| Blackrock, Inc. | 390.97K | ▼ 4.93K |
| Compass Financial Management LLC | 389.23K | ▼ 211.00K |
| Renaissance Technologies LLC | 342.59K | ▼ 37.90K |
| Geode Capital Management, LLC | 324.94K | 0 |
| Two Sigma Investments, LP | 234.86K | ▼ 24.32K |
| Vanguard Fiduciary Trust Co | 200.59K | ▲ 39.06K |
| Two Sigma Advisers, LP | 196.08K | ▼ 300 |
| Gagnon Securities LLC | 182.14K | 0 |
Held by 23 ETFs
Biggest fund positions in ATNM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 14, 26 | David Matthew T | other | 250,000 |
| Oct 14, 26 | David Matthew T | other | 250,000 |
| Oct 14, 26 | David Matthew T | other | 0 |
| Sep 3, 26 | Kamal Adeela | other | 0 |
| Sep 3, 26 | Kamal Adeela | other | 0 |
| Sep 3, 26 | Heeger Steffen Wilhem | other | 0 |
| Sep 3, 26 | Heeger Steffen Wilhem | other | 0 |
| Sep 2, 26 | Shetty Ajit | other | 92,400 |
| Sep 2, 26 | Shetty Ajit | other | 61,600 |
| Sep 2, 26 | Nicholson, C. David | other | 94,200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATNM coverage
Recent articles, reports, and earnings notes.
No research on ATNM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATNM report →Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress
prnewswire.com · Nov 17
Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy
prnewswire.com · Nov 12
Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy
prnewswire.com · Nov 11
Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development
prnewswire.com · Nov 9
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
prnewswire.com · Nov 4
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
prnewswire.com · Nov 4
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models
prnewswire.com · Nov 2
Actinium Pharmaceuticals Announces Inducement Grant to New Employee
prnewswire.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.